BCL2 and Parkinson disease: β-Asarone inhibits the PERK/CHOP/Bcl-2/Beclin-1 pathway to alleviate ER stress and excessive autophagy in Parkinson’s disease rat models, reducing PERK phosphorylation, CHOP expression, and Beclin-1 release, while increasing Bcl-2 levels to inhibit autophagy (Ning et al., 2019).